Traditional Chinese medicine decoction for treating acute lung injury and preparation method thereof

Abstract

The invention belongs to the technical field of medicaments for treating lung injury, and discloses a traditional Chinese medicine decoction for treating acute lung injury and a preparation method thereof, the traditional Chinese medicine decoction comprises the following raw material components in parts by mass: 28-32 parts of gypsum, 13-17 parts of trichosanthes peel, 13-17 parts of scutellaria baicalensis, 13-17 parts of thunberg fritillary bulb, 18-22 parts of houttuynia cordata, 13-17 parts of reed stem, 8-12 parts of semen armeniacae amarae, 13-17 parts of platycodon grandiflorum and 8-12 parts of liquorice. The preparation method comprises the following steps: S1, weighing the raw material components; s2, uniformly mixing the raw materials, dividing into three parts, respectively soaking in warm water, decocting with slow fire, filtering with three layers of gauze after taking the juice, and mixing the medicine liquid for three times; and S3, concentrating the mixed liquid medicine in a water bath box, cooling the liquid medicine at normal temperature, and storing the cooled liquid medicine in a refrigerator. The invention provides a traditional Chinese medicine decoction for treating acute lung injury and a preparation method thereof. The traditional Chinese medicine decoction is used for treating, relieving or preventing the acute lung injury.

Description

Technical Field

[0001] The invention relates to the technical field of medicaments for treating acute lung injury, in particular to a traditional Chinese medicine decoction for treating acute lung injury and a preparation method thereof. Background Art

[0002] Acute lung injury (ALI) is caused by injury factors (such as sepsis, endotoxin shock, acute respiratory distress syndrome virus, aspiration pneumonia, contusion, pulmonary embolism, etc.), which causes damage to alveolar epithelial cells and capillary endothelial cells, resulting in diffuse pulmonary interstitial and alveolar edema. The clinical manifestations are respiratory distress, accompanied by refractory hypoxemia, decreased lung compliance, and diffuse inflammatory infiltration. The coronavirus SARS-CoV2 can cause respiratory tract infection and damage the basic structure of the lungs. Neutrophils and macrophages gather at the damaged site to produce an inflammatory cascade reaction. Damage to the lung epithelium can cause bacterial adhesion and invasion, causing co-infection and acute lung injury. Pneumonia infected with lipopolysaccharide (LPS) is the most common cause of acute lung injury, which can induce the secretion of various inflammatory factors in the body, activate the inflammatory system, and trigger the occurrence of acute lung injury. At present, the clinical treatments for acute lung injury mainly include drug therapy and mechanical ventilation. The use of protective ventilator treatment strategies can provide some help in treating patients with acute lung injury, but it has not been able to effectively reduce the mortality rate of patients. Drug therapy has a certain effect on controlling the disease, but there is still no effective treatment.

[0003] With the progress of research on the anti-inflammatory immune mechanism of traditional Chinese medicine and its active ingredients, more and more traditional Chinese medicines are used in clinical practice. Traditional Chinese medicines have the characteristics of long-lasting and mild effects, few side effects, and significant improvement of clinical symptoms, which are more in line with the treatment needs of acute lung injury. Therefore, it is of great significance to study traditional Chinese medicine decoctions for the treatment of acute lung injury. Summary of the invention

[0004] The present invention aims to provide a Chinese medicinal decoction for treating acute lung injury and a preparation method thereof, so as to treat, alleviate or prevent acute lung injury.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] A traditional Chinese medicine decoction for treating acute lung injury comprises the following raw material components by weight: 28-32 parts of gypsum, 13-17 parts of trichosanthes peel, 13-17 parts of scutellaria baicalensis, 13-17 parts of thunbergia thunbergii, 18-22 parts of houttuynia cordata, 13-17 parts of reed stems, 8-12 parts of bitter almonds, 13-17 parts of platycodon grandiflorum, and 8-12 parts of liquorice.

[0007] Further, it includes the following components in proportion by mass: 30 parts of gypsum, 15 parts of Trichosanthes peel, 15 parts of Scutellaria baicalensis, 15 parts of Fritillaria thunbergii, 20 parts of Houttuynia cordata, 15 parts of Reed stems, 10 parts of bitter almonds, 15 parts of Platycodon grandiflorum, and 10 parts of Licorice.

[0008] A method for preparing the above-mentioned Chinese medicinal decoction for treating acute lung injury comprises the following steps:

[0009] S1. Weigh the following raw material components: 28-32 parts of gypsum, 13-17 parts of Trichosanthes peel, 13-17 parts of Scutellaria baicalensis, 13-17 parts of Fritillaria thunbergii, 18-22 parts of Houttuynia cordata, 13-17 parts of Reed stem, 8-12 parts of Bitter Apricot, 13-17 parts of Platycodon grandiflorum, and 8-12 parts of Licorice;

[0010] S2, after mixing the raw materials in step S1 evenly, divide them into three parts, soak them in warm water respectively, and boil them over a low fire, filter the juice through three layers of gauze, and mix the three filtered medicinal liquids;

[0011] S3. Place the mixed liquid medicine in a water bath to concentrate it. After the liquid medicine cools to room temperature, store it in a refrigerator.

[0012] Further, in S2, the first portion of the raw material is soaked in 8 times warm water for 0.5 h, and then boiled and simmered for 4 h; the second and third portions of the raw material are respectively soaked in 6 times warm water for 0.5 h, and then boiled and simmered for 2 h, and the juice is filtered through three layers of gauze.

[0013] The beneficial effects of the technical solution are:

[0014] The present invention uses LPS-induced acute lung injury model in mice as experimental object, and verifies through experiments that the Chinese medicine decoction of the present invention has significant therapeutic effect on the lung function of acute lung injury mice, and can significantly increase PIF, PEF and MV of model mice; significantly improve inflammatory cell infiltration in alveolar cavity, alveolar wall capillary dilation, congestion and bronchial dilation of model mice; significantly improve the expression of ZO-1, ZO-2 and VE-Cadherin in pulmonary vascular endothelium of model mice. Therefore, the Chinese medicine decoction of the present invention can treat acute lung injury, protect damaged lung tissue, and can be used as a medicine for preventing and treating acute lung injury; and the Chinese medicine decoction has few side effects, good efficacy, high feasibility and considerable prospect value. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is a representative result of HE staining of the normal control group in Example 2 of the present invention (bar=200 μm);

[0016] Figure 2 This is a representative result of HE staining of the model control group 1 in Example 2 of the present invention (bar=200 μm);

[0017] Figure 3 This is a representative result of HE staining of the model control group 2 in Example 2 of the present invention (bar=200 μm);

[0018] Figure 4 This is a representative picture of HE staining results of the high-dose group of traditional Chinese medicine decoction in Example 2 of the present invention (bar=200 μm);

[0019] Figure 5 This is a representative result of HE staining of the medium-dose group of the Chinese herbal decoction in Example 2 of the present invention (bar=200 μm);

[0020] Figure 6 This is a representative result diagram of VE-Cadherin expression in the normal control group in Example 2 of the present invention (immunohistochemistry, bar=200 μm);

[0021] Figure 7 This is a representative result diagram of VE-Cadherin expression in the model control group 1 in Example 2 of the present invention (immunohistochemistry, bar=200 μm);

[0022] Figure 8 This is a representative result diagram of ZO-1 expression in the model control group 1 in Example 2 of the present invention (immunohistochemistry, bar=200 μm);

[0023] Fig. 9 This is a representative result diagram of ZO-2 expression in the high-dose group of traditional Chinese medicine decoction in Example 2 of the present invention (immunohistochemistry; bar=200 μm);

[0024] Fig.10 This is a representative result diagram of ZO-2 expression in the medium-dose group of the Chinese medicine decoction in Example 2 of the present invention (immunohistochemistry; bar=200 μm);

[0025] Fig.11 This is a representative result diagram of ZO-2 expression in the low-dose group of traditional Chinese medicine decoction in Example 2 of the present invention (immunohistochemistry; bar=200 μm);

[0026] Fig.12 This is a representative result diagram of ZO-2 expression in the dexamethasone control group in Example 2 of the present invention (immunohistochemistry; bar=200 μm);

[0027] Fig.13 This is a representative result diagram of VE-Cadherin expression in the normal control group in Example 2 of the present invention (immunofluorescence, bar=20 μm);

[0028] Fig.14This is a representative result diagram of VE-Cadherin expression in the model control group 1 in Example 2 of the present invention (immunofluorescence, bar=20 μm);

[0029] Fig.15 This is a representative result diagram of VE-Cadherin expression in the model control group 2 in Example 2 of the present invention (immunofluorescence, bar=20 μm);

[0030] Fig.16 This is a representative result diagram of VE-Cadherin expression in the high-dose group of the Chinese medicine decoction in Example 2 of the present invention (immunofluorescence, bar=20 μm);

[0031] Fig.17 This is a representative result diagram of VE-Cadherin expression in the medium-dose group of the traditional Chinese medicine decoction in Example 2 of the present invention (immunofluorescence; bar=20 μm). DETAILED DESCRIPTION

[0032] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments:

[0033] Example 1

[0034] A traditional Chinese medicine decoction for treating acute lung injury comprises the following raw material components in proportion by mass: 30g of gypsum, 15g of trichosanthes peel, 15g of scutellaria baicalensis, 15g of fritillaria thunbergii, 20g of houttuynia cordata, 15g of reed stem, 10g of bitter almond, 15g of platycodon grandiflorum and 10g of liquorice.

[0035] The method for preparing the above-mentioned Chinese medicine decoction for treating acute lung injury comprises the following steps:

[0036] S1. Weigh the following raw materials: 30g of gypsum, 15g of Trichosanthes peel, 15g of Scutellaria baicalensis, 15g of Fritillaria thunbergii, 20g of Houttuynia cordata, 15g of Reed stem, 10g of Bitter Apricot, 15g of Platycodon grandiflorum, and 10g of Licorice root;

[0037] S2, after mixing the above raw materials evenly, divide them into three parts, soak the first part of the raw materials in 8 times warm water for 0.5h, boil and simmer for 4h, and filter the juice through three layers of gauze; soak the second and third parts of the raw materials in 6 times warm water for 0.5h, boil and simmer for 2h, and filter the juice through three layers of gauze; mix the three filtered medicinal liquids;

[0038] S3. Place the mixed liquid medicine in a water bath and concentrate it to 0.735g of the experimental high dose per ml. After diluting it 2 times, it will be 0.367g / ml (medium dose), and after diluting it 4 times, it will be 0.147g / ml (low dose). After the liquid medicine is cooled to room temperature, store it in a refrigerator at 4°C.

[0039] Example 2

[0040] This embodiment conducted a pharmacodynamic test, in which the effect of a Chinese herbal decoction on lipopolysaccharide (LPS)-induced acute lung injury (ALI) mice and its possible mechanism of action were studied, providing an experimental basis for clinical application.

[0041] Methods: C57BL / 6J mice were selected as the experimental system, and the mouse acute lung injury model was established by a single tracheal injection of lipopolysaccharide (LPS) (5 mg / kg). 24 membrane-forming mice were divided into model control group 1, model control group 2, three groups of high, medium and low doses of Chinese herbal decoction, and dexamethasone control group according to their weight, with 4 mice in each group. Another 4 mice were taken as the normal control group. After grouping, the mice in the low, medium and high dose groups of Chinese herbal decoction were given 0.147g / mL, 0.367g / mL and 0.735g / mL of the test solution by gavage, respectively, with a dosing volume of 0.4ml / mouse, once a day, for 7 consecutive days. The mice in the dexamethasone control group were intraperitoneally injected with a dose of 1mg / kg, 10ml / kg, once a day, for 3 consecutive days, the mice in the model control group 2 were intraperitoneally injected with 0.9% saline 10ml / kg, and the mice in the normal control group and model control group 1 were given 0.4ml / mouse of pure water by gavage. At the end of drug administration, the lung function (PIF, PEF, MV) of mice in each group was detected by whole body plethysmography system for unrestrained awake animals. After the lung function test, the mice were euthanized, and fresh lung tissues of 2 mice in each group were obtained for pathological histological examination using HE staining, and the expression changes of ZO-1, ZO-2, and VE-Cadherin in the vascular endothelium were detected by tissue immunohistochemistry and immunofluorescence.

[0042] Test results:

[0043] (1)Weight

[0044] During the experiment, the body weight of mice in the model group was basically the same as that of the normal control group, and no statistical difference was found; the body weight of the high, medium and low dose groups of the Chinese herbal decoction and the dexamethasone control group was basically the same as that of the model group. This shows that lipopolysaccharide membrane formation has no effect on the body weight of animals, and the high, medium and low doses of the Qingfei Lifen Decoction Chinese herbal decoction and dexamethasone have no effect on the body weight of animals in the model group.

[0045] (2) Pulmonary function test results

[0046] Compared with the model control group, the PIF, PEF and MV of mice in the high-dose group of dexamethasone and Qingfei Lifen Formula Chinese medicine decoction were significantly increased (p < 0.05), the PIF, PEF and MV of mice in the medium-dose group of Chinese medicine decoction were significantly increased, but only PIF and MV showed statistical differences (p < 0.05), and the PIF, PEF and MV of mice in the low-dose group of Chinese medicine decoction were also increased, but no statistical differences were found (p > 0.05), indicating that the Chinese medicine decoction of the present invention has an improving effect on the lung function of mice with acute lung injury after oral administration for 5 days, among which the high and medium doses have obvious therapeutic effects.

[0047] (3) Pathological examination results

[0048] like Figure 1-5 The following are the HE staining results of the normal control group, model control group 1, model control group 2, high-dose Chinese herbal decoction group, and medium-dose Chinese herbal decoction group. After LPS modeling, a large number of inflammatory cells infiltrated the alveolar cavity of mice, pulmonary consolidation was observed in some areas, and capillaries were significantly dilated and congested, indicating that LPS can cause acute lung injury in mice. After administration of Chinese herbal decoction and dexamethasone, the infiltration of inflammatory cells in the alveolar cavity of mice, dilation and congestion of alveolar wall capillaries, and bronchial dilation were alleviated or improved to varying degrees, but the effect was most obvious in the high-dose group of dexamethasone and Chinese herbal decoction, and the effect was not obvious in the low-dose group.

[0049] (4) Expression of ZO-1, ZO-2, and VE-Cadherin in the pulmonary vascular endothelium

[0050] like Figure 6-17 The results of immunohistochemistry and immunofluorescence tests are shown in the figure. Compared with the model control group, the expression of ZO-1, ZO-2, and VE-Cadherin in the vascular endothelium of mice in the high-dose group of Chinese medicine decoction was significantly increased after 7 days of administration (p < 0.01 or p < 0.05). The expression of ZO-1, ZO-2, and VE-Cadherin in the vascular endothelium of mice in the medium and low-dose groups was also increased after 7 days of administration, but no statistical difference was found (p > 0.05).

[0051] In summary, under the experimental conditions, high-dose Chinese herbal decoction has a significant therapeutic effect on the lung function of mice with acute lung injury, which can significantly increase the PIF, PEF and MV of model mice; significantly improve the inflammatory cell infiltration in the alveolar cavity, alveolar capillary dilation, congestion and bronchial dilation of model mice; and significantly increase the expression of ZO-1, ZO-2 and VE-Cadherin in the pulmonary vascular endothelium of model mice. The medium-dose group also has a certain improvement effect, but the low-dose group has a weaker effect.

[0052] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, several modifications and improvements can be made without departing from the technical solution of the present invention, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

Claims

1. A Chinese medicinal decoction for treating acute lung injury, characterized in that: The invention comprises the following raw material components in proportion by mass: 28-32 parts of gypsum, 13-17 parts of trichosanthes peels, 13-17 parts of scutellaria baicalensis, 13-17 parts of thunbergia thunbergii, 18-22 parts of houttuynia cordata, 13-17 parts of reed stems, 8-12 parts of bitter almonds, 13-17 parts of platycodon grandiflorum and 8-12 parts of liquorice.

2. The Chinese medicinal decoction for treating acute lung injury according to claim 1, characterized in that: The invention comprises the following components by weight: 30 parts of gypsum, 15 parts of trichosanthes peels, 15 parts of scutellaria baicalensis, 15 parts of thunbergia thunbergii, 20 parts of houttuynia cordata, 15 parts of reed stems, 10 parts of bitter almonds, 15 parts of platycodon grandiflorum and 10 parts of liquorice.

3. A method for preparing a Chinese medicinal decoction for treating acute lung injury as claimed in claim 1, characterized in that: The following steps are involved: S1. Weigh the following raw material components: 28-32 parts of gypsum, 13-17 parts of Trichosanthes peel, 13-17 parts of Scutellaria baicalensis, 13-17 parts of Fritillaria thunbergii, 18-22 parts of Houttuynia cordata, 13-17 parts of Reed stem, 8-12 parts of Bitter Apricot, 13-17 parts of Platycodon grandiflorum, and 8-12 parts of Licorice; S2, after mixing the raw materials in step S1 evenly, divide them into three parts, soak them in warm water respectively, and boil them over a low fire, filter the juice through three layers of gauze, and mix the three filtered medicinal liquids; S3. Place the mixed liquid medicine in a water bath to concentrate it. After the liquid medicine cools to room temperature, store it in a refrigerator.

4. The method for preparing the Chinese medicinal decoction for treating acute lung injury according to claim 3, characterized in that: In S2, the first portion of raw materials was soaked in 8 times warm water for 0.5 h, boiled and simmered for 4 h, and the juice was filtered through three layers of gauze; the second and third portions of raw materials were soaked in 6 times warm water for 0.5 h, boiled and simmered for 2 h, and the juice was filtered through three layers of gauze.

Images